These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11751777)

  • 1. Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers.
    Scanvic-Hameg A; Chachaty E; Rey J; Pousson C; Ozoux ML; Brunel E; Andremont A
    J Antimicrob Chemother; 2002 Jan; 49(1):135-9. PubMed ID: 11751777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK; Fung KS; Cheng AF
    Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.
    Johnson AP; Warner M; Hallas G; Livermore DM
    J Antimicrob Chemother; 2000 Jul; 46(1):125-8. PubMed ID: 10882701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
    Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
    Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
    Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
    Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant Enterococcus faecium from humans.
    Kieke AL; Borchardt MA; Kieke BA; Spencer SK; Vandermause MF; Smith KE; Jawahir SL; Belongia EA;
    J Infect Dis; 2006 Nov; 194(9):1200-8. PubMed ID: 17041845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD; Lin ML; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinupristin/dalfopristin-resistant enterococci of the satA (vatD) and satG (vatE) genotypes from different ecological origins in Germany.
    Werner G; Klare I; Heier H; Hinz KH; Böhme G; Wendt M; Witte W
    Microb Drug Resist; 2000; 6(1):37-47. PubMed ID: 10868806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.
    McDonald LC; Rossiter S; Mackinson C; Wang YY; Johnson S; Sullivan M; Sokolow R; DeBess E; Gilbert L; Benson JA; Hill B; Angulo FJ
    N Engl J Med; 2001 Oct; 345(16):1155-60. PubMed ID: 11642231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria.
    Gander S; Finch R
    J Antimicrob Chemother; 2000 Jul; 46(1):61-7. PubMed ID: 10882690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.